

Cadmium Toxicity on Arterioles Vascular Smooth Muscle Cells of Spontaneously Hypertensive Rats

Benny Washington^{1*}, Shunta Williams², Patrice Armstrong¹, Charlie Mtshali¹, John T. Robinson¹, and Elbert L. Myles¹

¹Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA

²Department of Microbiology, Meharry Medical College, Nashville, TN 37208, USA

*Correspondence to Dr. Benny Washington. Email: bWASHINGTON@tnstate.edu

Received: 20 November 2005 / Accepted: 20 June 2006 / Published: 31 December 2006

Abstract: Cadmium (Cd) is frequently used in various industrial applications and is a ubiquitous environmental toxicant, also present in tobacco smoke. An important route of exposure is the circulatory system whereas blood vessels are considered to be main stream organs of Cd toxicity. Our previous results indicate that cadmium chloride (CdCl₂) affects mean arterial blood pressure in hypertensive rats. We hypothesized that Cd alters the intracellular calcium transient mechanism, by cadmium-induced stimulation of MAPKs (ERK 1 & 2) which is mediated partially through calcium-dependent PKC mechanism. To investigate this hypothesis, we exposed primary cultures of vascular smooth muscle cells (VSMCs) from wistar kyoto (WKY) and spontaneously hypertensive rats (SHR) to increased concentrations of CdCl₂ on cell viability, expression of mitogen-activated protein kinases (MAPKs/ERK 1 & 2), and protein kinase C (PKC) which are activated by Cd in several cell types. The results from these studies indicate that CdCl₂ decreased cell viability of both SHR and WKY VSMCs in a concentration dependent-manner. Viability of both cell types decreased 33±5.3 (SHR) and 39±2.3% (WKY) when exposed to 1 µM CdCl₂, whereas, 8 and 16 µM reduced viability by 66±3.1 and 62±4.5% in SHR cells. CdCl₂ increased ERK 1 & 2 in a biphasic manner with maximum increase occurring when cells are exposed to 1 and 4 µM in SHR VSMCs, whereas, a reduction in ERK 1 and 2 is observed when WKY cells are treated with 2 µM. The results also indicate that CdCl₂ increased PKC α/β in both SHR and WKY VSMCs with a greater increase in expression in SHR VSMCs. In addition, the [Ca²⁺]_i chelator, BAPTA, suppressed the CdCl₂ effect, whereas, the PKC inhibitor, GF109203X, reduced the CdCl₂ induced-effect on PKC expression. The present studies support the hypothesis that Cd can be a risk factor of hypertension through dysfunction of vascular smooth muscle cells under certain conditions.

Keywords: Protein kinase C; mitogen-activated protein kinase; ERK 1; ERK 2; vascular smooth muscle cells.

Introduction

Cd is frequently used in various industrial activities and is a ubiquitous environmental toxicant, also present in tobacco smoke. An important route of exposure is the circulatory system whereas blood vessels are considered to be main stream organs of Cd toxicity. Cd exposure via the respiratory system has been studied [1] and it has been reported that Cd causes apoptosis in various cell types *in vitro* [2]. We have shown that CdCl₂ increases blood pressure in both SHR and WKY rats and chronic exposure of VSMCs of rats with CdCl₂ leads to apoptosis (unpublished results). However, the mechanism involved

in the elevation of blood pressure and the apoptotic effects of CdCl₂ has not been determined.

The evidence indicates that the mitogen-activated protein kinase (MAPK) cascade is involved in the regulation of cell growth, differentiation, and various cellular stress responses which is mediated through intracellular signal transduction in response to a variety of stimuli [3, 4]. More recently, MAPK has been studied in response to other stresses [5-7] to gain an understanding of the MAPK signaling mechanisms, specifically, in cardiovascular disorders [8, 9].

Also, the cellular mechanisms involved in triggering and development of atherosclerosis induced by Cd may

include MAPKs and other signal transduction systems, such as protein kinase C (PKC). Since the discovery that PKC is the high affinity intracellular receptor of phorbol esters, it is widely accepted that PKC plays a role in the regulation of proliferation and differentiation [10, 11]. As these processes involve nuclear regulatory control, it is thought that PKC must be involved in mediating nuclear responses to both mitogenic and differentiation factors [12, 13]. In fact, substantial evidence indicates a direct role for PKC in linking cell membrane receptor binding events to responses at the genome level.

It is our hypothesis that CdCl₂ alters the calcium transient mechanism through cadmium-induced stimulation of MAPK (ERK 1 & 2) which is mediated partially through calcium-dependent PKC mechanism. In this study we are providing evidence to support this hypothesis by reporting the results of specific MAPKs and PKC- α/β activation following stimulation with CdCl₂ in VSMCs from a hypertensive phenotype. The results indicate that ERK 1 and 2 along with PKC- α/β are reduced or inhibited within 5 min of stimulation in SHR cells which may be the results of Cd competing with intercellular calcium ([Ca²⁺]_i) in activation of the pathways for these intermediates.

Materials and Methods

Materials

Dulbecco's Modified Eagle's medium was obtained from Cambrex BioScience (Walkersville, MD), fetal bovine serum, and penicillin/streptomycin, both purchased from Biowhittaker (Walkersville, MD). For experimental procedures, CdCl₂ was obtained from Sigma Chemical Company (St. Louis, MO) along with the calcium chelator, BAPTA-AM. The PKC inhibitor, GF109203X, was purchased from Tocris (Ballwin, MO). SDS-Polyacrylamide gels (precast) were ordered from BioRad Laboratories (Hercules, CA) and nitrocellulose membrane from Amersham Biosciences (Piscataway, NJ). Primary antibodies for MAPK and Protein Kinase C- α/β were ordered from Cell Signaling (Beverly, MA) and used for western blotting analysis. To detect and image the primary MAPK and PKC primary antibodies, Anti-rabbit IgG secondary antibodies (horseradish peroxidase linked) was obtained from Amersham Bioscience (Piscataway, NJ) and chemiluminescent (ECL) detection system was obtained from Pierce Biotechnology (Rockford, IL).

Cell Culture and Treatment

Vascular smooth muscle cells were obtained from Dr. Evangeline Motley (Meharry Medical College) and cultured in DMEM containing 10% fetal calf serum, penicillin, and streptomycin. Sub-cultured VSMCs from passages 3-12, used in the experiments, were seeded into conventional plastic tissue culture plates (Falcon) and cultured in DMEM containing 10% fetal calf serum in a

humidified atmosphere of 5% CO₂ and O₂. CdCl₂ was prepared in DMEM at 50 mM just before application. After cells were confluent, cells were incubated for the desired time periods with desired concentrations of CdCl₂.

Western Blot Analysis of MAPK and PKC Expression

Cells grown in 6 well plates were stimulated in the presence or absence of the desired concentrations of CdCl₂ at 37°C for specified durations. The reactions were terminated by the replacement of medium with 100 μ l of SDS-polyacrylamide gel electrophoresis buffer, pH 6.8, containing 62.5 mM Tris-HCl, 2% SDS, 10% glycerol, 50 mM dithiothreitol, and 0.1% bromophenol blue. Samples were sonicated briefly, followed by a one minute flash spin. Samples were then boiled for three min and centrifuged at 10,000 RPM for 5 min and supernatant (20 μ g) was subjected to a 10% SDS-polyacrylamide gel. Proteins in the gel were transferred to a nitrocellulose membrane using the semi-dry transfer method. The membrane was then blocked for non-specific binding for one hr with 5% non-fat dry milk. Primary antibodies specific for ERK 1 & 2 and PKC- α/β were gently rocked at 4°C over the membrane overnight and washed before the membrane was submerged in the secondary antibody for one hr. After washing, the membrane was incubated with secondary anti-rabbit antibodies and immunoreactive proteins were detected by the ECL.

Cell Viability

VSMCs viability was assessed by using trypan blue exclusion. Briefly, the cells were plated in wells of 6 –well cluster plate and grown to confluence for 48 hr. After treatment with CdCl₂, the cells were harvested by trypsin digestion, centrifuged at 1200 x g for 10 min at 4°C, and examined by adding an equivalent volume of a 0.4% trypan blue solution to an aliquot of the re-suspended cells. The re-suspended cells were incubated for 5 min and the stained and unstained cells were counted by means of a hemocytometer.


Statistics

Each experiment was repeated at least 3 times. The effects of cadmium or antagonists on MAPK and PKC expression were plotted using a statistic program, prism (GraphPad Software, San Diego, CA). We performed densitometric analysis of images from Western blotting with a molecular imaging system (BioRad). The results are the mean \pm SEM and compared by ANOVA of Student-t test where appropriate. A value of p<0.05 was considered significant.


Results

The effects of CdCl₂ on VSMCs viability are shown in figure 1. CdCl₂ (1-16 μ M) exposure of SHR and WKY VSMCs for 24 hr resulted in a statistically significant

concentration-related decrease in cell viability for both cell types. VSMCs viability for both cell types decreased 33 and 39%, respectively, when cells were treated with 1 μM of CdCl_2 . A significant decrease in cell viability was observed between the two cell types of 6%. Maximum decreases in cell viability observed after cells were treated with concentrations of CdCl_2 (8 and 16 μM) were 66 ± 3.1 and $62 \pm 4.5\%$ for SHR cells. This decrease in cell viability was observed to be significantly higher in WKY cell types, 63 ± 1.5 and $75 \pm 5.0\%$, respectively.




A: CdCl_2 effect on cell viability of SHR VSMCs




B: CdCl_2 effect on cell viability of WKY VSMCs

Figure 1: Effect of CdCl_2 on Cell viability of SHR and WKY vascular smooth muscle cells. Cell viability was assessed following incubation of cells with CdCl_2 for 24 hr using the trypan blue exclusion method. The mean levels of cell viability for treating cells with 1-16 μM of CdCl_2 on SHR VSMCs (A) were 66.6 ± 10.5 , 44.0 ± 12.8 , 33.7 ± 2.6 , and $37.5 \pm 6.8\%$ and WKY VSMCs (B) were 61 ± 13.5 , 45.5 ± 5.9 , 36.3 ± 2.7 , and $25.3 \pm 9.5\%$, respectively. The data are the mean \pm SEM of 3 different experiments. *Significantly different from time-matched control, $p < 0.05$.



A: CdCl_2 effect on MAPK expression of SHR VSMCs




B: CdCl_2 effect on MAPK expression of WKY VSMCs


Figure 2: A concentration dependent effect of CdCl_2 on expression of ERK 1 & 2 in VSMCs of (A) SHR and (B) WKY rats. VSMCs were stimulated with 1-16 μM of CdCl_2 . Cell were harvested in lysis buffer as described in Material and Methods, and equal protein concentrations (20 μg) were analyzed on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane. ERK 1 & 2 were determined by measuring specific phosphorylated ERK 1 & 2 (pp44 ERK-1 and pp42 ERK-2) by western blot. Densitometric analysis of western blots was done to quantify the magnitude of change in phosphorylation of MAPKs induced by CdCl_2 . Bar graph represents intensities of ERK 1 & 2 bands. The data are the mean \pm SEM of 3 to 4 different experiments. * $p < 0.05$ compared to time-matched control.

We also investigated the effect of CdCl₂ on expression of ERK 1 and 2. The results indicated that CdCl₂ activated ERK 1 and 2 in a biphasic manner in VSMCs of SHR. Maximum activation of ERK 1 and 2 was observed with 1 and 4 μM of CdCl₂ with 8 μM having similar effects on MAPK expression as that was observed with 4 μM. Expression of ERK 1 and 2 increased 80±3.6 and 85±4.2%, respectively, of control and was suppressed with 2 and 16 μM of CdCl₂ shown in figure 2A. Treating WKY VSMCs with similar concentrations of CdCl₂, expression of ERK 1 and 2 was initially reduced with 2 μM, whereas, 4 μM increased expression by 77±5.1% of control shown in figure 2B. It was also observed that 16 μM reduced expression of ERK 1 and 2 in a similar manner as that observed when VSMCs of SHR were treated with similar concentrations of CdCl₂.

The time of activation of ERK 1 and 2 in VSMCs with 4 μM CdCl₂ is shown in figure 3A and 3B. The expression of ERK 1 and 2 was suppressed for the first 2 min in SHR VSMCs. Five (5) min of exposure seem to reduce expression which was followed by a time-dependent increase in expression at 15 min in SHR VSMCs shown in figure 3A. This increase remained present up to 60 min of exposure, whereas, the expression of ERK 1 and 2 increased dramatically within 5 min after exposing WKY VSMCs to CdCl₂. Maximum expression of ERK 1 and 2 in WKY cells was observed within 5 min of exposure followed by a reduction in ERK 2 for 10-60 min shown in figure 3B.




A: Time Course on the effect of CdCl₂ on ERK 1 & 2 Expression in SHR




B: Time Course on the effect of CdCl₂ on ERK 1 & 2 Expression in WKY

Figure 3: A time course effect of CdCl₂ on expression of ERK 1 & 2 in VSMCs of (A) SHR and (B) WKY rats. VSMCs were stimulated with 4 μM of CdCl₂ for the specified time 1-60 min. Cells were harvested in lysis buffer as described in Material and Methods, and equal protein concentrations (20 μg) for each sample were analyzed on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane. ERK 1 & 2 were determined by measuring specific phosphorylated ERK 1 & 2 (pp42 ERK-1 and pp42 ERK-2) by western blot.

Next, we examined the effect of CdCl₂ on PKC expression in both SHR and WKY VSMCs shown in figure 4A and 4B. CdCl₂ increased PKC-α/β expression in a concentration and time dependent manner with maximum expression observed within 15 min of exposing SHR cells to 4 μM, whereas, maximum expression of PKC-α/β was obtained in WKY cells when cells were exposed 30 min or longer. We also investigated whether the [Ca²⁺]_i and PKC pathway are link to the CdCl₂ effect observed in SHR cells. GF109203X, the PKC inhibitor, reduced the CdCl₂ induced-effect by 32±2.5% whereas BAPTA suppressed the CdCl₂ effect which is shown in figure 5.



A: Time Course on the effect of CdCl₂ on PKC Expression in SHR



B: Time Course on the effect of CdCl₂ on PKC Expression in WKY

Figure 4: A time-dependent effect of CdCl₂ on expression of PKC in VSMCs of SHR (A) and WKY (B). Cells were stimulated with 4 μM of CdCl₂ for 1-60 min. Cells were harvested in lysis buffer as described in Material and Methods, and equal protein concentrations (20 μg) were analyzed on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane. PKC-α/β expression was determined by measuring specific phosphorylated PKC-α/β by western blot.

The antagonistic effects of various antagonists on CdCl₂ induced PKC Expression




Figure 5: The antagonistic actions of GF109203X (GF) and BAPTA on CdCl₂ induced stimulation of PKC-α/β_{II} expression in SHR VSMCs. Cells were stimulated with 4 μM of CdCl₂ for 5 min following treatment for 1 hr with each antagonist. PKC-α/β expression was determined by measuring specific phosphorylated PKC-α/β by western blot. Densitometric analysis of western blots was done to quantify the magnitude of change in phosphorylation of MAPKs induced by CdCl₂. Bar graph represents intensities of MAPK bands. The data are the mean± SEM of 3 to 4 different experiments. *p<0.05 compared to time-matched control.

Discussion

It has also been shown that Cd exposure rapidly increases inositol 1, 4, 5,-triphosphate and then triggers Ca^{2+} mobilization in various cell types [14, 15]. Also, it has been shown that pre-treatment with an intracellular Ca^{2+} chelator, BAPTA/AM, suppresses CdCl_2 induced MAPKs in renal epithelial and CCRF-CEM cells [16]. In the present study, we examined the effect of CdCl_2 on MAPK and PKC expression in VSMCs of SHR. The results indicate that CdCl_2 decreased cell viability of both SHR and WKY cells in a concentration dependent manner. Furthermore, it appears that CdCl_2 activates ERK 1 & 2 in a biphasic manner in SHR VSMCs and that PKC α/β expression is more sensitive to CdCl_2 effects than what was observed in WKY VSMCs. Also, CdCl_2 induced effect is suppressed with the intracellular Ca^{2+} chelator, BAPTA and is reduced significantly with the PKC inhibitor, GF109203X which may indicate that the mediated effect of Cd is link to the mobilization of calcium through the MAPK and PKC pathways which share a role in the propropagating of the signal generated by Cd.

It is also known that MAPKs mediate intracellular signal transduction in response to a variety of stimuli [3,4]. The MAPK family members are themselves activated by reverse dual phosphorylation on the Thr and Tyr residues in the catalytic domain. Three major MAPKs have been identified, the extra cellular signal-regulated kinases (ERK1 and 2), the stress-activated protein kinases c-Jun NH2-terminal kinases (JNK) and p38 mitogen activated protein kinases. It seems that Cd exposure rapidly increases inositol 1, 4, 5,-triphosphate and then triggers Ca^{2+} mobilization in various cell types [14, 15] and that pre-treatment with an intracellular Ca^{2+} chelator, BAPTA, suppresses CdCl_2 -induced JNK. The results from these studies showed that intracellular Ca^{2+} plays a role in CdCl_2 -induced activation of ERK, JNK, and 38 MAPK in CCRF-CEM cells [17].

We previously observed that in hypertensive rat, Cd increased blood pressure and heart rate. Also Cd exposure has been implicated in Hypertension and atherosclerotic lesion [18, 19]. The frequencies of ten diseases in a Cd-contaminated region in the Netherlands [20] were investigated and it was found that a significantly higher frequency for atherosclerosis occurred which indicated a relationship between Cd exposure and cardiovascular disease epidemiologically [21] and in Cd exposed pigeons, not only hypertension but also atherosclerotic lesion was observed [18].

In conclusion, it was found that Cd can decrease cell viability and can activate MAPKs and PKC expression in SHR VSMCs. An intracellular calcium-dependent pathway is suggested to be involved in the Cd mediated effect which may lead to its contribution to hypertension through the dysfunction of VSMCs.

Acknowledgments- This work was supported in part by grants from NIH/NCRR/RIMI #RR11808 and The

Academy of Applied Science (REAP Program). The authors also extend their thanks to Rudolph Woodberry (Tennessee State University, Nashville, USA) for his technical support.

References

1. Oberdorster, G.: Pulmonary deposition, clearance and effects of inhaled soluble and insoluble cadmium compounds. *IARC. Sci. Publ.*, **1992**, 189-204.
2. Watjen, W.; Haase, H.; Biagioli, M.; Beyersmann, D.: Induction of apoptosis in mammalian cells by cadmium and zinc. *Environ. Health. Perspect.* **2003**, *110 (suppl. 5)*, 865-867.
3. Lewis, T. S.; Shapiro, P. S.; Ahn, N. G.: Signal transduction through MAP kinase cascades. *Adv. Cancer. Res.*, **1998**, *74*, 49-139.
4. Puddicombe, S. M.; Davies, D. E.: The role of MAP kinases in intracellular transduction signal transduction in bronchial epithelium. *Clin. Exp. Allergy*, **2000**, *30*, 7-11.
5. Ueda, Y.; Hirai, S.; Osada, S.; Suzuki, A.; Mizuno, K.; Ohno, S.: Protein kinase C activates the mEK-ERK pathway in a manner independent of RAS and dependent on RAS. *J. Biol. Chem.* **1996**, *271(38)*: 23509-23512.
6. Seger, R.; Krebs, E. G.: The MAPK signaling cascade. *FASEB J.*, **1995**, *9*:726-735.
7. Kyriakis, J. M.; Avruch, J.: Protein kinase cascades activated by stress and inflammatory cytokines. *Bioessays*, **1996**, *18*: 567-577.
8. Washington, B.; Mtshali, C.; Williams, S.; Li, J. D.; Shaw, B.; Gwathmey, J.: Ethanol-induced mitogen activated protein kinase activity mediated through protein kinase C, *Cell. And Mol. Bio.*, **2005**, *49(8)*, 1351-1356;
9. Euguchi, S.; Matsumoto, T.; Motley, E. D.; Utsunomya, H.; Inagami, T.: Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. *J. Biol Chem.*, **1996**, *271*:14169-14175.
10. Clemens, M. J.; Trayner, I.; Menaya, J.: The role of the kinase C isoenzymes in al., the regulation of cell proliferation and differentiation. *J. Cell Sci.*, **1992**, *103*:881-887.
11. Nishizuka, Y.: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science*, **1992**, *258*:607-614.
12. Olson, E. N.; Burgess, R.; Staudinger, R.: Protein Kinase C as a transducer of nuclear signals. *Cell growth differentiation*, **1993**, *4*:699-705.
13. Buchner, K.: Protein Kinase C in the transduction of signals toward and within the cell nucleus. *Eur. J. Biochem.*, **1995**, *228*:211-221.
14. Smith, J. B.; Dwyer, S. D.; Smith, L.: Cadmium evokes inositol polphosphates formation and calcium stimulates and zinc antagonizes. *J. Biol. Chem.*, **1989**, *264*: 7115-7118

15. Benters, J.; Floger, U.; Shafer, T.; Leibfritz, D.; Hechtenberg, S.; Beyersman, D.: Study of the interactions of cadmium and zinc ions with cellular calcium homeostasis using ¹⁹F-NMR spectroscopy. *Biochem. J.*, **1997**, *322*: 793-799.
16. Iryo, Y.; Matsuoka, M.; Wispriyono, B; Sugiura, T.; Igistu, H.: Involvement of the extracellular signal-regulated protein kinase (ERK) pathway in the induction of apoptosis by cadmium chloride in CCRF-CEM cells. *Biochem. Pharmacol.* **2000**, *60*: 1875-1882.
17. Matsuoka, M.; Igisu: Activation of c-Jun NH2-terminal kinase (JNK/SAPK) in LL-PK1 cells by cadmium. *Biochem Biophys Res Commun*, **1998**, *251*: 527-532.
18. Revis, N. W.; Zinsmeister, A. R.; Bull, R.: Atherosclerosis and hypertension induction by lead and cadmium ions: an effect prevented by calcium ion. *Proc. Natl. Acad. Sci. USA*, **1981**, *78*, 6494-6498.
19. Ross, R.: The pathogenesis of atherosclerosis: a perspective for the 1990's. *Nature (London)*, **1993**, *362*, 801-809.
20. Houtman, J. P.: Prolonged low-level cadmium intake and atherosclerosis. *Sci. Total Environ.* **1993**, *138*, 31-36.
21. Carroll, R. E.: The relationship of cadmium in the air to cardiovascular disease death rates. *J. Am., Med. Assoc.*, **1966**, *198*, 267-269.